Skip to main content
Signal8

ARS Pharmaceuticals, Inc. (SPRY)

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

ARS Pharmaceuticals, Inc. logo

ARS Pharmaceuticals, Inc.

NASDAQ:SPRYHealthcare
-7.65%$3.38
AH$3.44+1.78%vs close
Mkt Cap$336.13M
Float48.99M
O/S99.45M
Vol
$ Vol
RVOL
Inst Own91.2%
SI40.5%
Earnings
Dilution